

## **ISSUER QUARTERLY REPORT**

**For the Period ended September 30, 2013**

**VIRATECH CORP.**  
**4719 Quail Lakes Drive #G319**  
**Stockton, CA 95207**  
**Telephone Number: (209) 477-3030**

### **ISSUER'S EQUITY SECURITIES**

**Common Stock, authorized 2,000,000,000 shares**  
**par value \$.0001 per share.**  
**Preferred Stock, authorized 10,000,000 shares**  
**par value \$.0001 per share.**

### **TRANSFER AGENT**

**Standard Registrar and Transfer Co**  
**12528 S. 1840 E.**  
**Draper, UT 84020**  
**Ph. (801) 571-8844**

### **SECURITIES COUNSEL**

**Crawford Shaw**  
**230 Park Avenue**  
**10th Floor**  
**New York, NY 10169**  
**(917) 453-9986**

**Item 1. Name of the issuer and its predecessors (if any)**

The exact name of the issuer is VIRATECH CORP.

**Item 2. Address of the issuer's principal executive offices.**

Company Headquarters

Address 1: 4719 Quail Lakes Drive #G319 Stockton, CA 95207.

Phone: (209) 477-3030.

Email: [info@viratech.org](mailto:info@viratech.org)

Websites: <http://viratech.org>, <http://cancer.im>

**Item 3. Security Information**

Trading Symbol: VIRA

Exact title and class of securities outstanding: Preferred shares and common stock

CUSIP: 927647 107

Par or stated value: Preferred: par value \$.0001; Common par value: \$.0001

Total shares authorized: 2,000,000,000 common shares as of September 30, 2013; 20,000,000 preferred shares as of September 30, 2013

Total shares outstanding: 753,663,750 shares of common stock outstanding, of which 646,730,000 shares are subject to lockup agreements and 3,882,500 shares of Preferred stock outstanding as of September 30, 2013.

Additional class of securities: None

Transfer Agent

Name: Standard Registrar and Transfer Co.

Address 1: 12528 S. 1840 E., Draper, UT 84020

Phone: (801) 571-8844

Is the Transfer Agent registered under the Exchange Act? Yes

List any restrictions on the transfer of security: None

Describe any trading suspension issued by the SEC in the past 12 months: None

List any stock split, dividend, recapitalization, merger, acquisition, spin-off or reorganization either currently anticipated or that occurred within the past 12 months:

In December 2012, the Company entered into an agreement to purchase Cancer.im, Inc. in exchange for \$6.2 million in Company restricted common stock. The purchase was closed in the first quarter of 2013.

Cancer.im, Inc. has licensed to Cancer.im, a Utah non-profit corporation, <http://cancer.im>, the world's first experience-based social network resource site for cancer patients, survivors, advocates, and volunteers. Cancer.im's mission is to empower every cancer patient, regardless of their ability to pay, with the power to research their disease and to find, organize, and manage their own cancer support network. The goal of these support networks is to assist the patient in conserving needed energy by reducing the burden associated with their own daily trials and tribulations. Cancer.im will strive to convert this saved energy into a higher level of patient activity and a stronger determination to fight their disease.

As a result of its agreement with Cancer.im, a Utah non-profit corporation, Cancer.im, a Utah non-profit corporation has agreed to pay to the Company 30% of all revenues received by it from the operation of the web site, <http://cancer.im>, as well as reserving to the Company 100% of all advertising space and advertising revenues.

Version 2.0 of the web site was launched October 21, 2013. Viratech and its wholly owned subsidiaries have both licensed to and integrated various elements of their intellectual property into this new business platform of Cancer.im, which is a nonprofit foundation. Viratech will earn revenue from its development and operation of the [cancer.im](http://cancer.im) web site for Cancer.im by receiving a portion of donations to Cancer.im as compensation, and 100% of all advertising revenue generated from the site.

The Cancer.im vision is based on the Robert Ryan Cancer Protocol- a modular 15 part best practice guide on teaching and assisting cancer patients and their loved ones on the importance of Quality of Life and how to raise it when managing a diagnosis of cancer.

In 2013, nearly 1.6 million Americans will be diagnosed with cancer. Of that, 581,000 people are expected to die. Cancer accounts for 1 in every 4 deaths, second only to heart disease as the most common cause of death. The monetary cost seems irrelevant to the loss of life. Overall costs of cancer are projected to exceed \$201 billion in 2013: \$77 billion for direct medical costs (all health expenditures) as well as over \$124 billion for the indirect mortality costs.

One weapon on this war on cancer is Quality of Life (QoL). On October 27, 2007 Dr. Nikolaou, on behalf of Fox Chase Medical Center (a National Comprehensive Cancer Network) published a double blind placebo controlled study titled "Quality of Life (QOL) Supersedes the Classic Predictors of Survival in Locally Advanced Non-Small Cell Lung Cancer (NSCLC)." The study was designed to evaluate the role of QoL as a prediction for survival. Some 91 percent of patients completed a standardized QoL survey before treatment. All patients were followed for at least 17 months. What they found is quality of life emerged as the most significant predictor of overall patient survival.

"...We conducted two different statistical analyses including all the usual prognostic factors and either way, quality of life remained the strongest predictor of overall survival," "...What's more, if a patient's quality of life increased over time, we saw a corresponding increase in survival," said Dr. Benjamin Movsas of Henry Ford Hospital. This study concluded that by raising a Cancer Patients Quality of Life via the European Organization for Research and Treatment of Cancer QLQ-C30, you could directly lower the incidence of morbidity in a cancer patient, **regardless of treatment**.

Cancer.im's new social network includes useful tools such as a powerful news engine, Micro-Social Networks (MSNs) and content management systems. It provides the tools needed for cancer patients to maintain a high Quality of Life and enables members to be organized, informed, and empowered survivors, as well as provide them with research that is being done on new solutions for early cancer detection and treatment. There are many other features for those involved with cancer, including referrals of researchers and health care providers.

Unlike other networks, Cancer.im was designed by a team that is dedicated to specifically serve the unique needs of cancer patients and its community in a new easy-to-use format.

Many more tools are being added to enhance the 15 Modules designed to decrease morbidity in cancer patients by increasing the Quality of Life. There is the “Save-it” button that allows someone browsing the web to click a button and add the content or submit “Write-it” requests for publication to a Writer or Researcher portal. The Q&A section allows members to ask and answer questions. The “i-Know” button allows for contribution of content to a private repository of information.

The Cancer.im business platform can be used with other diseases besides cancer. Viratech Corp., which owns an exclusive license for use of the platform within the biotech arena has already sublicensed this platform with two other biotech business entities, with plans to integrate this deeper into its licensing market.

The Company sees Cancer.im as a perfect complement to its open source research platform. Where Viratech applies open source research in the area of protecting intellectual property so companies can promote and crowd source their ideas from concept to reality, Cancer.im harnesses the same social collaboration utilities to develop what we believe will become the first experience based search engine powered by social collaboration.

Through its experience-based search engine and next-generation technology, Cancer.im’s goal is to become the primary resource on the web for people affected by cancer, for the purpose of making a difference in their own lives and the lives of others.

The site was launched on February 19, 2013. Cancer.im harnesses social collaboration utilities to develop what Viratech believes will become the first experience-based search engine powered by social collaboration. The merger was consummated in February 2013.

Cancer.im is the first social network which has reversed engineered an evidence based medicine study which has shown that by increasing the quality of life of a cancer patient you can directly lower the incidence of morbidity regardless of treatment.

Cancer.im is positioning itself to have the first mover advantage by becoming the primary resource on the Web that people affected by cancer will turn to in order to make a difference in their own lives and the lives of others. Members can use Cancer.im to:

- Create and mobilize their own Patient Support Network;
- Learn from the wisdom of cancer survivors;
- Research all aspects of cancer;
- Organize their medical records, insurance, and research;
- Create a customized strategy based on their educated beliefs, values and resources;
- Create a proactive cancer prevention strategy.

Through its experience-based search engine and next-generation technology, Cancer.im’s goal is to become the primary resource on the web for people affected by cancer, for the purpose of making a difference in their own lives and the lives of others.

### **Item 3. Issuance History**

The events that resulted in changes in total shares outstanding by the issuer in the past two fiscal years and any interim period, are as follows:

Common stock activity for the years ended December 31, 2012 and 2011 and the interim period was as follows:

During the period ended September 30, 2013, the Company issued 1,959,000 shares of common stock for total cash proceeds of \$195,900, pursuant to Regulation D and Section 4(a)(2) of the Securities Act of 1933.

During the period ended September 30, 2013, the Company issued 130,000 shares of common stock to its CFO for services, pursuant to Section 4(a)(2) of the Securities Act of 1933. Shares were valued at \$0.10, the closing price on the date of grant, for total expense of \$7,400.

During the period ended September 30, 2013, the Company issued 1,959,000 shares of common stock to its shareholders per the terms of a lock up agreement in which the shareholders agreed not to transfer their ownership shares for a specified time period, pursuant to Section 4(a)(2) of the Securities Act of 1933. All shares were valued at \$0.10, as determined by management.

During the period ended September 30, 2013, the Company issued 21,500,000 shares of common stock for its acquisition of Cancer.im, pursuant to Section 4(a)(2) of the Securities Act of 1933. Shares were valued at \$0.29, the price on the day the merger was authorized.

During 2012, 50,000 shares of common stock were issued for services, pursuant to Section 4(2) of the Securities Act of 1933.

During 2012, 8,449,200 shares of common stock were issued to investors in the Company's private placement of common stock, pursuant to Regulation D and Section 4(2) of the Securities Act of 1933.

Common stock activity for the year ended December 31, 2011 was as follows:

During 2011, the issuer issued an aggregate of 600,000,000 shares of common stock and 3,500,000 shares of Preferred B stock for the purchase or licensing of intellectual property, pursuant to Section 4(2) of the Securities Act of 1933.

During 2011, the issuer issued an aggregate of 38,250,000 shares of common stock and 382,500 shares of Preferred B stock in a Share Exchange Agreement, pursuant to Section 4(2) of the Securities Act of 1933.

During 2011, the issuer issued an aggregate of 75,000,000 in exchange for debt, pursuant to Section 4(2) of the Securities Act of 1933.

During 2011, the issuer reserved an aggregate of 150,000,000 shares for its Incentive Stock Option Plan, pursuant to Section 4(2) of the Securities Act of 1933.

None of the above-issuances were made as a result of any offerings that were registered or qualified in any jurisdiction.

#### **Item 4. Financial Statements.**

The issuer's most recent financial statements, including balance sheet, statement of income, statement of cash flows, and financial notes, as of September 30, 2013 are attached hereto.

#### **Item 5. Describe the Issuer's Business, Products and Services.**

## A. A description of the issuer's business operations:

Viratech was organized on March 21, 2000. Viratech is an open source biotechnology development company engaged in the business of researching and developing cancer treatment protocols through the use of open source web based research networks. Viratech's common stock is quoted on the pink sheets under the trading symbol, VIRA.

## PLAN OF OPERATIONS - IN GENERAL

### Forward Looking Statements

This Report may be deemed to contain "forward-looking" statements. Examples of forward-looking statements include, but are not limited to (i) projections of revenues, income or loss, earnings or loss per share, capital expenditures, growth prospects, dividends, capital structure and other financial items, (ii) statements of plans and objectives of the Company or its management or Board of Directors, including the introduction of new products, or estimates or predictions of actions by customers, suppliers, competitors or regulating authorities, (iii) statements of future economic performance, and (iv) statements of assumptions underlying other statements and statements about the Company or its business.

The Company's ability to predict projected results or to predict the effect of any legislation or other pending events on the Company's operating results is inherently uncertain. Therefore, the Company wishes to caution each reader of the Memorandum to carefully consider specific factors, including competition for products; the uncertainty of developing or obtaining rights to new products that will be accepted by the market; the effects of government regulations and other factors discussed herein because such factors in some cases have affected, and in the future (together with other factors) could affect, the ability of the Company to achieve its projected results and may cause actual results to differ materially from those expressed herein.

### Industry

In 1968 Intel was co-founded by Gordon Moore who, in 1965, wrote a paper explaining what was needed to develop the advancement of the integrated circuit. This paper described, among other elements, the necessity of open source development, and later became one of three papers which collectively became known as "Moore's Law." The power of Moore's Law combined with the open source "knowledge sharing" collaboration is obvious. 10 years ago the "smart phone" you hold in your hand today would be the size of a desktop computer, and 20 years ago that computer would be the size of your house.

In 1971 Richard Nixon and the 91<sup>st</sup> Congress of the United States passed the National Cancer Act, in a report submitted to Congress titled "A National Program for The Conquest of Cancer" which stated "...In 1930 we were able to cure only about one case in five; today we cure one in three, but the cure rate can be improved by a better application of the *knowledge that we know today*."

Today, that "*better application of knowledge*" has been stifled by bureaucracy, capital market inefficiency and archaic intellectual property laws, which has reduced competition to an oligopoly of multinational corporations, who through the luxury of virtually no competition have actually thwarted medical innovation in the name of protecting corporate profits. The results are obvious; compared to the advancements of the integrated circuit, cancer research has gone nowhere.

Viratech's patent-pending method of allowing open source research and development of biotech inventions emulates the open source research and development of software which led to the huge current advance in information technology. Its premise is simply to use the social networking phenomena of Facebook, Twitter and LinkedIn, and apply it to the biotech world, where many new treatments and diagnostics are either gobbled up by Big Pharma and never developed, or never developed for lack of IP protection and financing. For example, Avastin, the leading cancer treatment drug by Genetech/Roche, which is used to treat metastatic cancers, such as colorectal, lung, kidney and ovarian cancers, reached \$2.66 billion in sales in the U.S. alone in 2012, and worldwide sales of \$5.98 billion worldwide. Avastin was released to the market 16 years ago and approved by the FDA for use in treating metastatic cancers in the U.S. in 2004-eight years ago. By contrast, in the past 16 years, cell phones were the size of bricks and now everyone has one in their pocket. In 2004, Facebook was first launched, and now has over 1 billion users, but

the content contributed by those billion users is trite and trivial, and doesn't harness the huge power of social networking.

In response to the current dilemma in biotech research and development, and in an effort to make open source development more attractive and less costly, Viratech has created an open source biotech research and development platform, based on creating and leveraging our intellectual property tool set and infrastructure, consisting of intellectual property protection via social collaboration. We have developed a platform converting social networking into a development collaboration tool. Using this platform, our members can protect their member's intellectual property, then, using the micro social network as a utility to promote and crowd fund the research and development, produce and commercialize the new biotech and cancer research technology. We have created a three-pronged attack on the development of an open source platform consisting of the following:

### ***Protect***

By keeping everything a trade "secret" there is not only a mass duplication of effort pertaining to similar competitive research, but the inability to communicate within a community for shared insights, advancing technologies, and obtaining needed support.

According to an analysis by the World Intellectual Property Organization in Geneva ([www.wipo.int](http://www.wipo.int)), only 47,921, or less than 1%, of the estimated 4,730,000 million concepts annually are patented or protected via other measure of intellectual property protection. This void of intellectual property protection stifles innovation, and creates a synthetic barrier of entry to new ideas and progress. This has been caused by an archaic intellectual property protection system which makes the ability of protecting intellectual property onus and ineffectual. This void leads to the 4 million plus ideas annually that are out there to not enjoy any form of intellectual property protection. Thus, they are forced into the cave of trade secret domain where individuals do not have the ability of promoting their technology – infact, they're hiding their technology. This is especially true in the biotech field, where large pharmaceutical companies buy up new technologies in medicine and shelve their development while they promote their own already developed and patent protected products. This has brought biotech innovation to a major standstill, caused by archaic intellectual property mechanisms. Because of this, bio tech innovation has been stifled. It has been stifled at the protection of profits of large multi-national bio tech companies who understand this infrastructure, who understand how to manipulate this archaic legal foundation for their benefit and gain at the behest of the smaller issue.

This first element of Viratech's toolset, IP protection, is complemented by the elements of Promotion and Production of the technology, all using custom tailored interactive pages within the Viratech Social Network, called Micro Social Networks, owned by each user of the site who creates a page. Any user generated content that is contributed to the Micro Social Network owner's site is, by Viratech's terms of service and a separate permission layer, owned by that Micro Social Network owner and protected by his or her copyright.

### ***Promote***

Members of the Viratech community first protect their intellectual property using our toolset. Once protected, they are encouraged, via our collaboration platform, to freely promote their new technologies by posting their research in the community as well as broadcasting, (press release and social media distribution) what they need to assist in the development and furtherance of their research. As members add content to Viratech (Research, Documents, Patents, Theories, Blog Entries, Photos, Videos, Audio, Bookmarks, etc.), they can easily place individual restrictions on which of their peers, business associates, development partners, CRO's, and Investors can have access to that particular content. Members control access to their stored information allowing each member to confidently share more information and collaborate more readily with other members knowing that an irrevocable provenance is created and stored, documenting which development partner had access to view and download particular information. Viratech has created an exclusive relationship with Newswire, Inc. to allow all of Viratech Members the ability of broadcasting all their news originated by one of their Viratech pages, free of cost. The news is picked up by Google as informative content, which is used to generate traffic to the member's micro social network page, where the information is archived, and picked up by Google whenever a person performs a search using contextual key words related to the member's content.

## ***Produce***

Using the second prong of the Viratech model, Promote, each Micro Social Network user can promote their technologies by broadcasting them through a newswire service, which gets picked up on Google through the key words in each article. Readers of the article are blocked by a pop-up that asks them to join the Micro Social Network. Production is a feature which allows Micro Social Network owners to raise money for the research, development, and production of their technologies through crowd funding.

Independent biotech research and development teams usually find themselves in a chicken and egg dilemma. They need results to get research and development financing while at the same time needing financing to conduct the research to prove the treatment/diagnostic efficacy. Independent researchers often succumb to this dilemma by giving up control and autonomy in the early stage of research which, in turn, lowers moral and motivation. With the passage of the Crowdfunding Act in April 2012 our members may be able to use their micro social network (MSN) additionally to raise funds, leading to development and production of their biotech products.

## **How the Viratech Open Source Network Protects Intellectual Property**

Viratech is a social network consisting of a uniquely designed, indexed collection of Micro Social Networks (MSN's), tied together by a Unified Navigation Element (UNE). MSN's are created by the member to be an interactive container of content the user wishes to communicate to the network.

Intellectual property (IP) is put into a private folder, where Social Intelligence Reports ("SIRs") are written about the different aspect of the Private IP. The Social Intelligence Reports are then broadcasted throughout the internet looking for research. Responses to research come to individual MSN's within the Viratech framework. Individuals joining and contributing to these MSN's must accept Viratech's Terms of Service ("TOS"). In the TOS members acknowledge that the User Generated Content ("UGC") that they generate (post, document upload, discussion etc.) is property of the MSN owner. This UGC then becomes an ever-growing expression of the private work product/idea, thus incorporating a copyrighted derivative expression around the base of the intellectual property seeking additional protection.

New user generated expressions are then sent directly to the owner of the MSN, in a central command/outlook environment where it can be sent to be:

1. Published as new content on any MSN under management by the member;
2. Written as an article or press release explaining a particular aspect;
3. Researched by a third party; or
4. Stored within the MSN owners private Body of Knowledge.

This mechanism thus allows the MSN owner the ability of leveraging the Social Network and recirculates the content in growing and organizing and expanding expression of knowledge which will achieve the following:

1. Create more content which can be broadcasted through the MSN;
2. Create more contextual key word traffic to the MSN from the broadcasted content in 1;
3. Create more UGC from the traffic in 2;
4. Capture the UGC in 3 and decide whether to Publish, Write, Research, or keep private;
5. Publish new UGC and repeat step 1.

The present landscape of traditional social networks has proven to be an excellent tool for networking, broadcasting information about oneself, and initiating relationships. Viratech believes that its unique toolset has the potential to encourage a higher level of collaboration among its members and to use that collaboration as an intellectual property protection mechanism within the community thus creating a symbiotic and synergistic self-sustaining network. Our present toolset allows members the ability to:

1. Create as many public and private Micro Social Networks (MSN's) as desired;



2. Allow the creator of MSN's to own all the User Generated Content (UGC) created within it;
  3. Allow the creator of MSN's to have permission and the toolsets necessary to communicate to all the MSN's members/fans;
  4. Allow the members of Viratech.org to manage all content, information and UGC created and generated for the various MSN in one central command; and
  5. Allow the creator of an MSN the ability of broadcasting news, press releases and articles concerning the MSN for the purposes of driving contextual news-driven traffic to the MSN;
- 1-5 above are then organized as a way to generate and organize content into a centralized Body of Knowledge which the owner of the various MSN's can use as an innovative intellectual property protection mechanism.

## **Viratech's Operative Intellectual Property**

### **Method of Converting a Derivative Expression of an Idea into Social Network Navigation Element. United States Patent Application 61859295**

Ideas are the engine of commerce, innovation and scientific advancement. They live in the world of the abstract and as such the use of them becomes cumbersome until they are quantified and harnessed via derivative expressions thereof. "Method of Converting a Derivative Expression of an Idea into a Social Network Navigation Element" is the process of taking an idea and, then, through a series of processes, including research and writing, breaking the idea into its separate distinct derivative expression thereof. This is combined by a second series of processes transforming the distinct derivative expressions of the original idea, into graphical icons representing the linear understanding of the derivative expressions. These icons are then embedded with the uniform resource locator of the representative websites or Micro Social Networks, consisting of the multimedia knowledge repository of the derivative expressions, for the purpose of creating a linear intellectual property protection mechanism.

### **Additional IP Licensed to Viratech for Open Source Development**

Viratech's CEO, Dr. Kevin Buckman, has developed different medical technologies, which have been licensed to Viratech to be developed by open source. Each license is from Dr. Buckman's holding company, Health Care Intellectual Properties, LLC, for a renewable term of five years, subject to the payment by Viratech to Health Care Intellectual Properties, LLC, a royalty of 2.5% of the gross sales of the licensed technology. The technologies are described in the patent section of this report. None of the technologies have undergone clinical trials or been approved by any government authority.

### **Subsequent events after September 30, 2013 include new provisional patents filed:**

**Viratech has the exclusive license for biotech research of the following intellectual property suite:**

### **Nonprovisional Utility Patent Application 13952653; Title of Invention: Method of Acquiring, Capturing, Organizing, Indexing, and Broadcasting Multiple Derivative Expressions of an Idea(s) via Social Networking, July 28, 2013.**

This is part of an exclusive license of provisional patent 61676934 from Health Care Intellectual Properties, LLC, to Viratech.

This patent pending technology allows for the creation of a social network infrastructure to gather, share, and broadcast ideas through a social network, while at the same time protecting ownership of content.

Through the process laid out in the patent application, the user is able to take intellectual property consisting of an original idea or invention and leverage it in combination with user generated content created via social networking to create multiple derivative expression of the original idea.

This intellectual property is very exciting due its importance for use in Social Networks and many other applications for medical and non-medical uses and licensing of this platform to other companies and foundations. Ideas are the engine of commerce, innovation and scientific advancement. They live in the world of the abstract until the derivative expressions of these ideas can bring them into useful and constructive existence. The complex structure laid out in this patent application ensures that intellectual property is not only acknowledged and protected, but also developed in a way that would not otherwise be possible due to the collective nature of collaboration around the idea. This technology can allow a better application of knowledge that has been stifled by bureaucracy, capital market inefficiency and archaic intellectual property laws, which have thwarted medical innovation. The results are obvious; compared to the advancements of the integrated circuit, cancer research has done very little. With tools included in this patent, the company believes this to be a plan to reverse this trend and allow for the rapid and open development more research, protection, and promotion of new ideas and solutions.

**TOPIC: Health Disease Screening**

Application Number: 61859191, title of Invention: Method of Health and Disease Screening, July 2013  
This is a method design to improve medical care with new methods for health and disease screening using categories of disease classification for large-scale population applications, a way to improve sensitivity and specificity of screening tests at less cost, a method of selecting tests based on statistical analysis that is then used for more targeted screening along with algorithms that can take into account risk factors, symptoms, genetics, history, and lifestyle to improve screening methodology, incorporating software technology to process information to be used in a social media platform to use with various methods of disease detection and allow for more targeted therapies.

**TOPIC: Device to Prevent Hemolysis**

Application Number: 61859195, Title of Invention: Device to Prevent Hemolysis, July 2013  
It is often difficult to get enough blood for finger-stick tests so patients or medical care workers tend to squeeze the finger to “milk” blood out of the pin prick, but this can cause significant hemolysis of these cells, which will interfere with troponin assays causing false positives and false negative tests, abnormally high potassium levels, and invalidate other tests. This is a method of preventing hemolysis during blood draw, finger stick, and blood blot, along with analysis for various other tests and assays to prevent an invalid sample in Point-of-Care Testing (POCT) by use of a kit that contains means for better blood flow and protects the finger stick site from the occurrence of hemolysis.

**TOPIC: Chemical Balancing and Homeostasis Therapy for Women**

Application Number:61859200 Title of Invention: Chemical Balancing and Homeostasis Therapy for Women, July 2013 This is a method to test and treat Breast, Cervical, Ovarian, and Uterine Cancers with the use of a homeostasis protocol with hormonal, chemical, nutrient, and pH balancing, along with immune support and use of directed monoclonal antibodies to more effectively destroy cancer cells and viruses that cause these cancers, and a method of making and enhancing a women’s wellness formula to create body homeostasis and for treating and preventing breast diseases, breast cancer, and other female related diseases, along with immune support.

**TOPIC: Method of Making and Using a Device to Warm the Breast Prior to, and to Assist with, the Elicitation of Fluid, as Part of a Nipple Aspirate Fluid Test Kit or Part of a Breast Ductal Therapy Infusion Kit or Breast Topical Therapy Protocol** Application Number:61859202, Title of Invention: Device to Warm the Breast to Obtain Nipple Aspirate Fluid July 2013. Each year approximately 200,000 new patients with breast cancer are diagnosed in North America, and 50,000 of those will die of the disease. Despite billions of dollars poured into research, public awareness, and improved treatment, the statistics have shown only modest improvement over the past twenty years. This patent describes a method of making and using a device to warm the breast prior to the attempted elicitation of fluid in conjunction with a

commercialized test nipple aspirate fluid kit, one of the components of which will be a heat source.

**TOPIC: Method of Making a Energy and Wellness Homeostasis Drink Formula to Support Metabolism, Proper Use of Glucose, a Method to Provide Better Use of Needed Nutrients**

Application Number: 61859204 Title of Invention: Energy and Wellness Formula for Metabolism

July 2013 As of the year 2000, one out of 4 kids will get diabetes, and obesity is already epidemic in children. Kids drink high fructose drinks, drinks with caffeine, phosphates and other substances that are harmful. These and other unhealthy foods and environmental toxins all contribute to other diseases, with or without obesity, such as but limited to: thyroid problems, autoimmune disease, hypertension, cardiac disease, breast cancer, breast disease, prostate cancer, and degenerative diseases. Early prevention is vital for better outcomes. This patent describes a method of making a kid's drink to promote healthy cells that tend to be lacking in kid's diets and in the face of illness.

**TOPIC: Disease Assessment via Social Networks and use of Tests**

Application Number 61859211 Title of Invention: Disease Assessment via Social Network

July 2013 Cancer and disease consist of many underlying problems, along with chemical abnormalities, DNA damage, and complex interactions in the body. This patent is designed to be a more effective way to find and treat cancer and disease by early detection and treatment of the underlying cellular environment and promotion of a cellular anticancer, antiviral, proper metabolic state and healthier cellular environmental terrain. This is a method of using a Multivariate individualized statistical analysis and a comprehensive method of preventing, treating and evaluating cancer and diseases with a social media platform using software analysis to integrate information for risk assessment, diagnosis, and treatment.

**TOPIC: Method of Making and Using a Universal Screening Health Testing Device that is a Metabolic and Wellness Testing Cart for Metabolic Syndromes and Diabetes with Measurements of VCO<sub>2</sub>, VO<sub>2</sub>, and Calculates a Respiratory Quotient, and other ways to Monitor and Evaluate Disease Risk and Treatment**

Application Number:61859227 Title of Invention: Assess and Treat Metabolic Impairment

July 2013 This is a method of making and using a universal screening health testing cart, testing for metabolic syndromes and diabetes with VCO<sub>2</sub>, VO<sub>2</sub>, a Respiratory Quotient (RQ), and other tests along with algorithms for assessing risk, diagnosis, treating and preventing pre-diabetic syndrome, metabolic syndrome, precancerous states, cancer, diabetes, heart disease, renal disease, precursors to many diseases, and various other medical conditions. This universal health screening tool is designed as a medical testing device; its test results are coupled with separate testing inflammation panels and other markers to screen for disease state with high amount of sensitivity which is desirable for initial health and disease screening.

**TOPIC: Antioxidizing Stable Omega EFA (Essential Fatty Acids)**

Application Number:61859254 Title of Invention: Stabilizing Omega Oils and Essential Fatty Acids July 2013 Recently there has been concern about having a healthier ratio of omega-6 to omega-3 fatty acids, which are essential for normal growth, development, and health, and a careful analysis of each individual is needed, including any genetic influences in metabolism, dietary and enzymatic differences, and chemical balances. This patent describes a method of stabilizing healthy oils with healthy nutrients for oral or Topical use as a capsule, gel, liquid, or other acceptable form, to prevent oxidation of oils prior to use, and to improve shelf-life. The response to a healthy ratio of oils can then be monitored to see best individual response to ingestion of these stabilized essential fatty acids.

**TOPIC: Universal Health Screening**

Application Number:61859208 Title of Invention: Universal Health and Metabolic Screening

July 2013 TOPIC: Assess and Treat Metabolic Syndrome This is a method to treat and assess diabetes and

metabolic syndrome by finding disease states such as inflammation and improper metabolism with tests combined with a Personal Risk Index, from which to prevent and treat these conditions by normalizing chemical imbalances, using a formula for controlling blood sugar, improving metabolism, providing electrolytes, nutrients, and minerals, improving use of fats and carbohydrates, increasing the energy production by the cells, and improve exercise tolerance with a nutraceutical formula and enhanced uptake of the ingredients with a Wellness

Index. This metabolic and diabetes homeostasis protocol is to improve the normal endocrine function to that of a normal human or animal that is lacking due to diabetes, Alzheimer's disease, metabolic imbalance, Syndrome X, patients with heart failure, autoimmune disease, chronic degenerative disease syndrome, abnormal lipid metabolism, cancer, malnutrition, and imbalance of insulin, glucagon, glucose, minerals, and enzymes involved in proper homeostatic metabolism and function.

**TOPIC: Evaluate and Treat Cancer and Viruses** Application Number:61859255 Title of Invention: Method of Treating Cancer and Viruses July 2013

There has been no universal cure for cancer. This is largely due to the understanding that cancer is a complex disease state of an abnormal state of the cells that can be caused by environmental factors, epigenetic factors, nutritional state, metabolic state and the chemical imbalances wherein cells that have become damaged can replicate more quickly in a state that lacks metabolic balancing. This patent describes a more effective way to evaluate and treat cancer and viruses through testing and monitoring, and by affecting the underlying cellular environment and promotion of a cellular, anticancer, antiviral, proper metabolic state and healthier cellular environmental terrain.

## **ADDITIONAL PATENTS**

**TOPIC: Lowering Morbidity Rate**

Provisional Application Number 61828542 Method of lowering a cancer patient's morbidity rate by increase the quality of life of a patient by leveraging a caused base electronic support networks May 2013. Summary This invention relates to a method of creating an Online Cause Based Social Support Network (SSN) for the benefit of the cancer patient community based on the modular adaption, construction and best practices implementation of the European Organization for Research and Treatment of Cancer (EORTC), Quality of Life Questionnaire-C30 (QLQ-C30). This invention relates to a method of creating an SSN for the benefit of the Cancer Community (CC) allowing the Beneficiary the ability of recruiting resources and support via an online collaborative based community. The SSN is made up of miniature social networks, called Micro Support Networks (MSN), which revolve around a single user, or Beneficiary, who is facing a particular challenge or obstacle related to Cancer. The SSN infrastructure requires users to register and participate according to a specific user type: Beneficiary, Advocate/Advisor, or Volunteer. The goal of each Micro Support Network is to raise the EORTC OLQ-30 score of the Beneficiary by assisting in: (1) removing all of the frustrations from every possible aspect of the Beneficiary's personal challenge or obstacle; (2) removing the anxiety from every possible aspect of the Beneficiary's personal challenge or obstacle (3) give the Beneficiary the ability of conserving energy by deploying online trained volunteers in the assistance of the Beneficiary's particular personal challenge or obstacle(s); (4) giving the Beneficiary empowered access to all information available on their situation/condition; (5) surrounding the Beneficiary with a support community of individuals who are currently experiencing , or who have already successfully experienced, the same situation, personal challenge or obstacle; (6) enabling the Beneficiary to create an informed and customized strategy that is molded to their unique value system or situation.(7) enabling the Beneficiary in having the highest confidence level in their course of action. (8) enabling the Beneficiary in sharing their experiences online for the future benefit of cancer patients. (9) enabling the Beneficiary online access to a core of trained volunteers in the particular personal challenge or obstacle. (10) enable the Beneficiary online access to a body of knowledge (BOK) compiled by volunteer research and input. (11) enable the Beneficiary, a feedback loop to instill a higher sense of control of the particular personal

challenge or obstacle(s). Clinical studies have shown that cancer patients who have an active support network outlive cancer patients who do not<sup>1</sup>. The underlying driver of this has to do with the coordinated and conscious effort of helping a cancer patient (Beneficiary) increases their Quality of Life (QoL). A study titled “Quality of Life (QOL) Supersedes the Classic Predictors of Survival in Locally Advanced Non Small Cell Lung Cancer (NSCLC) was designed to evaluate the role of quality of life (QoL) as a prediction for survival. Some 91 percent of patients completed a standardized quality of life survey before treatment. All patients were followed for at least 17 months. What they found is quality of life emerged as the most significant predictor of overall patient survival. By raising a Cancer Patients Quality of Life via the European Organization for Research and Treatment of Cancer (EORTC), Quality of Life Questionnaire-C30 (QLQ-C30) you could directly lower the incidence of morbidity in a cancer patient, regardless of treatment.

**Topic: Weight and Metabolism:** Weight and Metabolism Control Health Formula and Monitoring Provisional patent application November 2012

**Topic: Women’s Health:** Method of Making and Tracking Benefits of a Women’s Wellness Formula Provisional patent application November 2012

**Topic: Cancer Screening:** Manual Nipple Aspirate Fluid and Cervical Kit, Provisional patent application November 2012

**Topic: Decreasing health care costs via early screening, testing, treatment, and improving quality of care** Provisional Patent January 2013: This patent deals with the Health Care Crisis in the US that now costs over \$2 trillion a year, and we are now in a downward trend in our ability to cover health care costs according to experts. The many technologies in this patent may allow for a different approach. By finding the underlining problems in diseases with early detection and treatment, this may allow for disease prevention and improved methods of managing chronic disease with the use of our open source medical research and social network platforms. There is a serious need worldwide to find new ways to test and treat health related problems before they become too costly.

Viratech is developing ways to improve sensitivity and specificity of health screening tests at less cost. It also allows for more broad-based testing of the underlying conditions associated with disease. By finding and treating these conditions, Viratech hopes to not only reduce health care costs but also help create a paradigm shift for preventative medicine. The company plans to utilize our social networks and other resources for data mining and further clinical research to formulate best practices and to utilize individualized healthcare platforms that are include in the patent. This patent is expected to be used with platform that can help with new technologies for licensing, sublicensing, promotion, business development, and marketing. Using this model, the Company anticipates sublicensing of the technologies from this agreement to support its model of light touch, low overhead, and make a difference for health.

**Topic: Creating a Body of Knowledge**

**Utility Patent Application** 13952653, Title of Invention: Method of Acquiring, Capturing, Organizing, Indexing, and Broadcasting Multiple Derivative Expressions of an Idea(s) via Social Networking, July 2013 This is considered the Jumbo Patent by the Company for its ability to integrate information for many business purposes.

The following Ext patient applications are lapsing: Method of Capturing and Indexing an Individual Aspect of Knowledge via Unified Structured Element, and Method of Creating Critical Mass of a Social Network

via the Assignment and Recording of Value of Individual Social Network Member Activity. It is anticipated that these will be replaced with new and update patent applications.

### **Viratech Books**

Cancer.im's first of 235 books to be released on Amazon's Kindle platform, focusing on Cancer, *Find and Stop Breast Cancer*, by Dr. Kevin Buckman, was published on Amazon.com achieved number one on the 100 best-sellers in breast cancer on Amazon.com as of January 26, 2013. *Find and Stop Breast Cancer* is the result of decades of research by Dr. Buckman in the field of cancer, highly focused on breast cancer. The book provides information geared toward making a difference in early diagnosis and treatment, and focuses much of its content on prevention of breast cancer and alternatives. *Find and Stop Breast Cancer* addresses on what every woman needs to know about the prevention and treatment of breast cancer.

On February 13, 2013, the Company published its second of 235 books released on Amazon's Kindle platform, focusing on Cancer. The book, *Cancer Patient User Manual*, by Dr. Kevin Buckman and Cancer Advocate Chris Ryan, which achieved number 1 best-seller status for Oncology. The first book, *Find and Stop Breast Cancer*, became a best seller last month after only three days.

*Cancer Patient User Manual* is the result of decades of research in the field of cancer. The book provides all the information needed to help any cancer patient become proactive immediately and make a difference in fighting their disease, regardless of the treatment they now receive or is available to them.

According to the book, "Cancer.im ([www.cancer.im](http://www.cancer.im)) is working to find new screening tests for cancer and new modes of therapy. The site, which launched on February 15, 2013, includes a user friendly Mission Adaptive Plan (a MAP) that can be tailored for each user, and 15 modules for dealing with the disease, which are based on the *Robert Ryan Cancer Protocol*. Based on more than 19 medical studies on quality of life and associated longevity, following the *Robert Ryan Cancer Protocol* decreases the morbidity of cancer by increasing the quality of life by the use of these 15 steps which allows a cancer patient to be proactive. There is no charge for this service."

On March 5, 2013, the Company's e-book publication of "Reversing Diabetes" on Amazon's Kindle platform, by Dr. Kevin Buckman and Dr. Barkat Charania, became the number one best seller in alternative medicine and number one in diabetes. The book discusses many of the complications of diabetes, as well as methods of treatment.

Additional books have been launched with the Company's e-book publications.

### **Recent Developments**

#### **CANCER.IM**

In December 2012, the Company entered into an agreement to purchase Cancer.im, Inc. in exchange for \$6.2 million in Company restricted common stock. The purchase was closed in the first quarter of 2013.

Cancer.im, Inc. owns and operates <http://cancer.im>, the world's first experienced-based social network resource site for cancer patients, survivors, advocates, and volunteers. Cancer.im's mission is to empower every cancer patient, regardless of their ability to pay, with the power to research their disease and to find, organize, and manage their own cancer support network. The goal of these support networks is to assist the patient in conserving needed energy by reducing the burden associated with their own daily trials and tribulations. Cancer.im will strive to convert this saved energy into a higher level of patient activity and a stronger determination to fight their disease.

Unlike other social networks, Cancer.im was designed by a team that is dedicated to specifically serve the unique needs of those currently struggling with the disease. This new network combines databases of medical community knowledge, repositories of wisdom from cancer survivors, systems for helping cancer patients organize their records and various facets of their treatment, and tools that allow patients and their supporters to work together effectively. In short, Cancer.im provides everything a cancer patient, friend, or family member is looking for to help in the fight against the disease, all in one online location and easy-to-use format.

Clinical studies have confirmed that those cancer patients with an active support network of friends, family and other advocates outlive those who do not. Cancer.im's networking tools will empower every cancer patient to take control of their treatment by giving them ways to find, organize and manage their own cancer support network.

The Company sees Cancer.im as a perfect complement to its open source research platform. Where Viratech applies open source research in the area of protecting intellectual property so companies can promote and crowdsource their ideas from concept to reality, Cancer.im harnesses the same social collaboration utilities to develop what we believe will become the first experience based search engine powered by social collaboration.

Through its experience-based search engine and next-generation technology, Cancer.im's goal is to become the primary resource on the web for people affected by cancer, for the purpose of making a difference in their own lives and the lives of others.

The site was launched on February 19, 2013. Cancer.im harnesses social collaboration utilities to develop what Viratech believes will become the first experience-based search engine powered by social collaboration. The merger was consummated in February 2013.

Cancer.im is the first social network which has reversed engineered an evidence based medicine study which has shown that by increasing the quality of life of a cancer patient you can directly lower the incidence of morbidity regardless of treatment.

Cancer.im is positioning itself to have the first mover advantage by becoming the primary resource on the Web that people affected by cancer will turn to in order to make a difference in their own lives and the lives of others. Members can use Cancer.im to:

- Create and mobilize their own Patient Support Network;
- Learn from the wisdom of cancer survivors;
- Research all aspects of cancer;
- Organize their medical records, insurance, and research;
- Create a customized strategy based on their educated beliefs, values and resources;
- Create a proactive cancer prevention strategy.

Through its experience-based search engine and next-generation technology, Cancer.im's goal is to become the primary resource on the web for people affected by cancer, for the purpose of making a difference in their own lives and the lives of others.

## **WELLNESS BUILDER**

On January 18, 2013, the Company signed a letter of intent to provide a turnkey Social Network for Wellness Builder, Inc., a company engaged in the development of a series of nutraceutical products designed to combat the effects of stress, inadequate nutrition and exposure to environmental toxins.

Viratech will provide a turnkey Social Network, using its licensed patent pending technology platform, which Social Network will act as an engagement funnel for individual micro social networks within the

Social Network, to obtain and develop user generated content for the sole purpose of protecting, promoting and producing individual elements of Wellness Builder's business model. In exchange for the fully integrated system, Viratech will receive \$250,000, a royalty of 5% of the gross sales of all products developed with the use of the system, and a non-dilutable equity interest of 10% in Wellness Builder, Inc.

### **About Wellness Builder**

Our modern lifestyles are characterized by high levels of stress, inadequate nutrition and exposure to environmental toxins, which can deplete our bodies of nutrients and make us susceptible to disease. Wellness Builder applies proven research to formulate natural products designed to counteract the damage.

Wellness Builder, Inc. is engaged in the research and development of pharmaceutical and nutraceutical products derived from the research of Dr. Kevin Buckman. The company has an executive team for funding, distribution, and marketing of 12 products to sell pharmaceutical and nutraceutical products derived from decades of research by Dr. Kevin Buckman.

Dr. Buckman has created more than a dozen formulas which are intended to address the underlying needs of individuals suffering from what he calls "DDS" (Degenerative Disease Syndrome). This includes such maladies as gastrointestinal disorders, auto-immune diseases, asthma, arthritis, diabetes, arthritis, cancer, and heart disease

### **DIABETES.NET**

On February 21, 2013, the Company entered into a letter of intent to provide a turn-key Social Network for Diabetes Network Charities at <http://diabetes.net>, for \$250,000, plus 25% royalty from all revenue derived from the operation of the site.

Diabetes.net is the original diabetes network for researchers, physicians and healthcare professionals. Diabetes mellitus is a group of metabolic diseases characterized by improper metabolism due to the inability of the pancreas to produce enough insulin, or the lack of response of cells to the insulin that is produced. As of 2010, an estimated 285 million people worldwide were afflicted with diabetes, and the number is expected to almost double by 2030. In the United States the CDC has classified the disease as epidemic. Diabetes.net is the original diabetes network of researchers, physicians, and health care professionals, promoting research on diabetes treatments and cures for over 25 years.

B. Date and State (or Jurisdiction) of Incorporation: March 21, 2000, Nevada

C. The issuer's primary and secondary SIC Codes:

Primary SIC Code: 8000

Secondary SIC Code: 8731

D. The issuer's fiscal year end date:

December 31

E. Principal products or services, and their markets:



Viratech is an open source biotech research and development network, with the ability to leverage our intellectual property suite to encourage sharing and accelerate development of new therapies and diagnostic procedures. Our Intellectual property suite consist of tools which will; protect intellectual property via social collaboration; broadcast calls for research and or collaboration; consult and prepare material for the Investigational Review Board (IRB), Investigational New Drug (IND) and the Contract Research Organization (CRO); assist in financing research and development via charitable alliance in addition to offering general business consulting.

The Company's primary product and service is the management of a web-based platform allowing users to exchange information and experiences through online communication. It is a blend of traditional websites with the accelerated growth of social networks as advertisers will be better able to market their products to a targeted segment of online members actively seeking information, products and services of a particular topic. The Company's secondary products are our licensed proprietary cancer treatment technologies.

## **OUR TARGET MARKET**

In the U.S. alone, it is estimated that there are more than 10 million cancer survivors. Worldwide, that figure is over 24,000,000 million survivors. This year, in the US alone, it is projected that 1.3 million people will be diagnosed with cancer for the first time and 556,000 people will die of the disease. This makes cancer the leading cause of death for people under the age of 85 years old. The latest stat the Company has for the impact of Cancer in the US is from 2006, the direct cost of cancer was approximately \$78 Billion for direct medical costs and an estimated \$128 Billion for indirect costs (such as lost productivity and labor) bringing the total economic impact to \$206 Billion. This equates to an average direct medical cost of \$60,454 per patient per year and a lost productivity cost of \$97,454 per patient per year.

Further according to a report by the World Intellectual Property Organization in Geneva, ([www.wipo.int](http://www.wipo.int)) only 47,921 or 1% of the estimated 4,730,000 million concepts annually are patented or protected via other measure of intellectual property protection. This void of intellectual property protection stifles innovation and creates a synthetic barrier of entry for new ideas and progress.

Viratech is an open source Biotech research and development network leveraging our social collaborative website and our intellectual property suite to provide a platform encouraging the sharing of Biotech research for the sake of accelerating the development of new therapies and diagnostic procedures.

Our toolsets' fulcrum is a method of protecting intellectual property via social collaboration. Which leverages social networking activity and user generated content as a mechanism of converting patents and other intellectual property into index able expression of a copyright work product. Using our toolset, members of the Viratech community can protect their intellectual property thereby allowing them the freedom to post their research and solicit collaboration and assistance from other members as well as being able to broadcast via press releases and social media distribution what they need to assist in the development and furtherance of their research into commercial production.

As members add content to Viratech (Research Documents, Patents, Theories, Blog Entries, Photos, Videos, Audio, Bookmarks, etc.) they can easily place individual restrictions on which of their peers, business associates, development partners, CRO's, and Investors can have access to that particular content. Members control access to their information allowing each member to confidently share more information and collaborate more readily with other members knowing that an irrevocable provenance is created and stored which can show which development partner had access to, viewed and download particular intellectual property/content.

Our second toolset focuses around crowdfunding of early stage research and development capital needs. Independent Biotech research and development teams usually find themselves in a chicken and egg

dilemma. They need results to get research and development financing while at the same time needing financing to conduct the research to prove the treatment/diagnostic efficacy.

Independent researchers often succumb to this dilemma by giving up control and autonomy in the early stage of research to venture capital board members or large corporations, which in turn removes the entrepreneurial spirit, moral and motivation to innovate.

The Company believes that our intellectual property toolset within our social networking infrastructure has the potential of opening up the scientific community to share and collaborate on ideas, theories and know how to streamline the development of new therapies and diagnostics within the cancer research community.

## **REVENUE MODEL**

The Company will offer its basic services free. It expects to have two main sources of revenue from the operation of the Viratech website:

## **WEBSITE ADVERTISING & SPONSORSHIPS**

The Company expects its largest source of revenue to be from website advertisement and sponsorship sales. Advertising and sponsorship fees and rates will vary depending on page, placement, and size of the advertisement on the website. Premium fees will be charged for home page and section sponsorships while a lesser fee will apply to run scheduled advertisements which continuously rotate throughout the website. The Company anticipates that manufacturers of cancer-specific pharmaceuticals, products, and services will make up a large percentage of advertisement and sponsorship sales. However, the Company is promoting its advertising to a broad base of industries, including companies in the consumer products, travel, tourism, and other industries.

## **CONSULTATION AND TURN KEY SOCIAL NETWORK WEB SITES**

The Company expects its second form of revenue to come from providing turn-key niche social networks, including a license of the Company's patent pending platform to protect, promote and produce products in an open source environment.

## **LEGAL MATTERS**

In 2008, Michael Frungillo filed a lawsuit in New Jersey federal court, case number 08-908, against the company and its subsidiary, Never Submit, LLC, when the company was named Imperia Entertainment, Inc., as well as the company's counsel, who filed an answer and application for pro hac vice admission. The court entered a default judgment in 2009 over the company and its counsel in the amount of approximately \$300,000, which has been included in the company's balance sheet since 2009.

### **Item 6. Describe the Issuer's Facilities:**

The issuer rents its offices at 4719 Quail Lakes Drive, Stockton, California, on a month to month basis. The properties of the issuer include its website, <http://viratech.org>, and <http://cancer.im>, owned by Cancer.im, Inc., the wholly owned subsidiary of the issuer.

### **Item 7. Officers, Directors and Control Persons**

Names of Officers, Directors and Control Persons. The names of each of the issuer's executive officers, directors, general partners, and control persons (beneficial owners of more than five percent (5%) of any class of the issuer's equity securities), as of the date of this information statement:

Kevin Buckman, MD, Chief Executive Officer/Chief Medical Officer, Director and over 5% beneficial owner

Valerie Kidd, MD, Director

Aziz Kamali, MD, Director

Matt Heindel, Vice President

**Kevin Buckman, MD-Chief Executive Officer/Chief Medical Officer**

Dr. Kevin Buckman MD, FAAIM, MRO, is a best-selling author of medical books, and has been leading projects since 1969 when he started his first national environmental project and an Ecology Club at his college campus. He grew up in Los Angeles and was concerned about pollution and its effect on our health. He completed his Medical School training at USC and continued his training there in Internal Medicine. He has become an expert in Environmental Medicine.

He has served as Medical Director in various hospitals and institutions for over 20 years. He has served as a member of the Executive Committee for six years at St. Dominic's Hospital in Manteca, California. He has written over ten patents for new medical and environmental technologies. From 1986 to 1997 there were more than 50 Physicians on his roster. He also served as Medical Director for Dameron Hospital EMS Liaison from 2002 to 2003. He became Board Certified in Emergency Medicine and a Fellow of the American Board of Emergency Medicine in 1990.

He has received numerous Certifications and Specialty Training in the field of Medicine. He is a Fellow in the American Association of Integrated Medicine, and a Board Certified Medical Review Officer. His other Specialties include: Internal Medicine, Forensic Medicine, Chinese Medicine and Acupuncture. He has over 30 years of hospital and clinical experience and has served on over 15 hospital committees.

He has presented research and given lectures at numerous hospitals and at International Medical Conferences and has traveled in 68 countries.

He has received Post Graduate Training at Stanford University School of Business, and attended seminars with the Securities Exchange Institute. He is the founder of the International Health Institute, a non-profit organization for a healthier environment. He has served as CEO for Lifeline BioTechnologies, Inc. a publically-traded company, and he successfully advanced the medical technologies for the company as well as fund raising, and made International presentations. He has numerous Medical Publications and has written books about health.

During the last twenty years he has worked to advance a number of medical technologies with a focus on the underlying causes of medical conditions, the early detection of disease, preventive medicine, and non-harmful new methods of medical treatment.

**Valerie Kidd, MD – Director**

Dr. Kidd received her BA in Chemistry from UC Davis, College of Letters and Science in 1980. She received her MD at University of California at Irvine, College of Medicine in 1984. She completed a Family Practice Residency Program at San Joaquin General Hospital from July 1984 to July 1987. She became first Board Certificated in Family Practice in 1987, then again in 1993, 2000, and 2007. Dr. Kidd is an active member of the American Academy of Family Physicians since 1987. She has been practicing medicine at Lodi Memorial Hospital since 2006. Since 2006, Dr. Kidd has held the following positions:

**Clinical Positions:**

1987-1988, Staff Physician, Employee Health Services, San Joaquin General Hospital  
1988-1991, Staff Physician, Lincoln Family Medical Group, Douglas Road, Stockton  
1991-1995, Staff Physician, Employee Health Services, Modesto, Stanislaus County  
1995-1996, Physician, California State University Stanislaus Student Health Center  
1996-2006, Staff Physician, Employee Health Services Clinic, San Joaquin General Hospital  
2007-March 2009, Family Medicine Physician, St Joseph's Medical Group of Stockton  
2007-March 2009, Medical Director, University of Pacific, Cowell Wellness Center Student Health  
2006-present, Staff Physician, Lodi Memorial Hospital Urgent Care Clinic  
2006-present, Staff Physician, Lodi Memorial Occupational Med Clinic

**Teaching Positions:**

1988-2003, University of Pacific, Physical Therapy Guest Lecturer  
1987-1991, Clinical Preceptor, San Joaquin Family Practice Residency  
1991-1996, Clinic Preceptor, Stanislaus Family Practice Residency  
1996-2003, Clinic Preceptor, San Joaquin Family Practice Residency

**Aziz Kamali, MD. – Director**

Dr. Kamali was born and raised in Jalalabad, in eastern Afghanistan. He obtained his secondary education in Kabul and did his undergraduate studies at the University of Afghanistan in Kabul. Dr. Kamali comes from a large family of medical, legal and engineering professionals who have been very active with the current development of Afghanistan, following in the footsteps of their father, Mohammed Shirin Kamali, a judge in eastern Afghanistan. Dr. Kamali is a Diplomate of the American Board of Internal Medicine.

Dr. Kamali is an associate clinical professor at the University of California, Davis, School of Medicine, in Sacramento, California. He did his postgraduate training in England and has a full registration with the British General Medical Council. He is a Fellow of the American College of Physicians and an Associate Fellow of American College of Cardiology.

**Matt Heindel- Vice President/Business Development**

Mr. Heindel spent nearly 30 years in the medical industry emphasizing the commercialization of Women's Health technologies. In 2005, Mr. Heindel was one of the early employees of NeoMatrix and was instrumental in the development of HALO, a breast cancer risk assessment tool which significantly improved the health of cancer patients while simultaneously minimizing the financial burden of the disease. Mr. Heindel's role at the start-up company ranged from selling the first units, creating the marketing launch plans to becoming the clinical expert for the company. Mr. Heindel was directly involved in guiding the company to revenue generation of over \$1M with over 200 devices in use including sales in several key international markets. In 2009, Mr. Heindel was key in recruiting

Breast Surgeons who are key industry opinion leaders and commencing clinical data gathering necessary for cost reimbursement. In 2007 Mr. Heindel became the company's Chief Operating Officer responsible for sales, marketing, manufacturing, RA/QA and clinical programs.

Prior to NeoMatrix, Mr. Heindel was a minority owner and Vice President of Sales and Marketing for Prism Enterprises, a company whose primary products serviced the ob-gyn market. By rebuilding the company's sales and marketing division with key personnel upgrades and by making strategic acquisitions in 2002, the new owners took Prism Enterprises from a bankrupt company to an acquisition target of Cooper Surgical to whom it was sold for a significant return in 2003.

Mr. Heindel began his medical career with McGaw, Inc. an intravenous solutions and device company. During his 16 year career at McGaw, Inc. Mr. Heindel progressed from a sales representative to Vice President of International Sales when the company was acquired by B. Braun in 1998. While at McGaw, Inc. Mr. Heindel spent two years in the Middle East where his passion for International Markets emerged. Mr. Heindel has also served as Senior Vice-President of Worldwide Sales and Marketing for Quidel, a rapid diagnostics company focusing in the field of Women's Health.

Mr. Heindel brings a unique combination of skills and experience in domestic and international marketing of capital and disposable products within the medical field. His many years in the medical industry have afforded him a vast array of key distributors and relationships with domestic and international sales representatives as well as access to the medical industries key thought leaders. Mr. Heindel is dedicating his part time efforts to the Company until such time as the Company receives funding.

#### **Rachel Boulds – Chief Financial Officer**

From August 2009 to the present, Ms. Boulds has been engaged in her sole accounting practice, preparing full disclosure financial statements for public companies to comply with GAAP and SEC requirements. Since February 3, 2012, she has served as CFO of Independent Film Development Corporation. From August 2004 through July 2009, she was employed as an Audit Senior for HJ& Associates, LLC, where she performed audits and reviews for public and private companies, prepared financial statements to comply with GAAP and SEC requirements, performed analytical procedures and substantive testing for all financial statement accounts, researched, resolved and communicated technical accounting issues, and formulated management recommendations for process and internal control improvements. From 2003 through 2004, Ms. Boulds was employed as Audit Senior for Mohler, Nixon and Williams, planning and performing audits, reviews and compilations, preparing form 550 for filing with the Dept. of Labor, reviewing policies and operating procedures of a company's benefit plan to recommend improvement of operations and insure compliance with the Department of Labor's rules and regulations, prepared financial statements to comply with reporting and disclosure requirements under ERISA, performed analytical procedures and substantive testing for all financial statement accounts, researched, resolved and communicated technical accounting issues, formulated management recommendations for process and internal control improvements, worked closely with third party administrators to coordinate the receipt of necessary information in order to perform audits in a timely manner and meet filing deadlines, and supervised and trained new staff. From September 2001 through July 2003, Ms. Boulds worked as an ABAS Associate for PriceWaterhouseCoopers, providing auditing services to public and private companies, performing analysis and substantive testing on balance sheets and income and expense statement components, reviewed client's revenue recognition policies to see that they were in compliance with relevant accounting standards, reviewed and documented clients' internal control policies and procedures and made recommendations for improvements, supervised and coached new associates, assisted in preparing full disclosure financial statements, provided clients with adjusting journal entries and recommendations to improve procedures, and worked with clients to maximize engagement efficiency and meet reporting deadlines.

From April 2000 through February 2001, she was employed as an eCommerce Accountant for the Walt Disney Group's GO.com.

**B. Legal/Disciplinary History**

None of the foregoing persons have in the last five years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);
2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;
3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or
4. The entry of an order by a self-regulatory organization that permanently or temporarily barred, suspended or otherwise limited such person's involvement in any type of business or securities activities.

**Item 8. Third Party Providers.**

Legal Counsel

Name: Crawford Shaw  
Address: 230 Park Avenue  
10th Floor  
New York, NY 10169  
Phone: (917) 453-9986  
Email: shawcrawford@gmail.com

Accountant or auditor

Name: Rachel Boulds, CPA  
Address: 6371 S. Glen Oaks Street  
Murray, UT 84107  
Phone: (801) 230-3945

Investor Relations Consultant

None

Other Advisor

None

I, Kevin Buckman, certify that:

1. I have reviewed this quarterly disclosure statement of Viratech Corp.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement fairly present in all material respects the financial condition, results of operation and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

Date: November 4, 2013

/s/ Kevin Buckman

Kevin Buckman, Executive Officer

**VIRATECH CORP.**

**INDEX TO CONSOLIDATED FINANCIAL STATEMENTS**  
(UNAUDITED)

Consolidated Balance Sheets as of September 30, 2013 and December 31, 2012	2
Consolidated Statements of Operations for the Three and Nine Months ended September 30, 2013 and 2012	3
Consolidated Statements of Cash Flows for the Nine Months ended September 30, 2013 and 2012	4
Consolidated Statement of Stockholders' Equity (Deficit) as of September 30, 2013	5
Consolidated Notes to the Financial Statements	6

**Viratech Corp.**  
**Consolidated Balance Sheets**  
(unaudited)

	September 30, 2013	December 31, 2012
<b><u>ASSETS</u></b>		
Current Assets:		
Cash	\$ 3,038	\$ 61,584
Total Current Assets	3,038	61,584
Goodwill	6,235,000	-
Intellectual property	169,000	169,000
Total Assets	\$ <u>6,407,038</u>	\$ <u>230,584</u>
<b><u>LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)</u></b>		
Current Liabilities:		
Accounts payable	\$ 100,000	\$ 100,000
Accrued officer compensation	2,500	-
Notes payable	204,000	200,000
Total Liabilities	<u>306,500</u>	<u>300,000</u>
Stockholders' Equity (Deficit):		
Preferred Series A, \$.0001 par value, 5,000,000 shares authorized, 10 shares issued and outstanding	-	-
Preferred Series B, \$.0001 par value, 5,000,000 shares authorized, 3,882,500 shares issued and outstanding	388	388
Common stock, \$.0001 par value, 2,000,000,000 shares authorized 753,663,750 and 726,830,550 issued and outstanding, respectively	75,366	72,683
Stock subscription receivable	-	(2,500)



Additional paid in capital		8,129,871	1,577,254
Deficit accumulated during the development stage		(2,105,087)	(1,717,241)
<b>Total Stockholders' Equity (Deficit)</b>		<b>6,100,538</b>	<b>(69,416)</b>
Total Liabilities and Stockholders' Equity	\$	<u>6,407,038</u>	\$ <u>230,584</u>

The accompanying notes are an integral part of these unaudited consolidated financial statements.

**Viratech Corp.**  
**Consolidated Statements of Operations**  
**(unaudited)**

	For the Nine Months Ended September 30,		For the Three Months Ended September 30,	
	2013	2012	2013	2012
Revenue	\$ 10,500	\$ -	\$ -	\$ -
Operating Expenses:				
Professional fees	18,401	8,825	1,200	2,500
Website development	77,855	17,012	21,822	3,819
Loss on impairment	-	723,932	-	723,932
Officer compensation	13,900	-	4,400	-
General and administrative	288,190	35,096	10,425	19,362
<b>Total operating expenses</b>	<b>398,346</b>	<b>784,865</b>	<b>37,847</b>	<b>749,613</b>
Loss from operations	(387,846)	(784,865)	(37,847)	(749,613)
<b>Net Loss</b>	<b>\$ (387,846)</b>	<b>\$ (784,865)</b>	<b>\$ (37,847)</b>	<b>\$ (749,613)</b>
Net loss per share	\$ (0.00)	\$ (0.00)	\$ (0.00)	\$ (0.00)
Weighted average shares	<u>749,958,957</u>	<u>722,483,193</u>	<u>753,649,837</u>	<u>723,665,643</u>

The accompanying notes are an integral part of these unaudited consolidated financial statements.

**Viratech Corp.**  
**Consolidated Statements of Cash Flows**  
**(unaudited)**

	For the Nine Months Ended September 30,	
	2013	2012
Cash flows from operating activities:		
Net loss	\$ (387,846)	\$ (784,865)
Adjustments to reconcile net loss to total cash used in operations:		
Common stock issued for services	7,400	-
Common stock issued for lock up	195,900	-
Loss on impairment	-	723,932
Changes in assets and liabilities:		
Increase in accruals	2,500	-
Net cash used in operating activities	(182,046)	(60,933)
Cash flows from investing activities:	-	-
Cash flows from financing activities:		
Contributed capital	2,000	-
Proceeds from notes payable	4,000	-
Proceeds from the sale of common stock	117,500	71,984
Net cash provided by financing activities	123,500	71,984
Net increase (decrease) in cash	(58,546)	11,051
Cash at beginning of period	61,584	2,831
Cash at end of period	\$ 3,038	\$ 13,882

Cash paid for:

Interest	\$	-	\$	-
Taxes	\$	-	\$	-

The accompanying notes are an integral part of these unaudited consolidated financial statements.

**Viratech Corp.**  
**Statement of Stockholders' Equity**  
**(unaudited)**

	Common Stock		Preferred Stock		Additional paid in capital	Stock subscription receivable	Deficit accumulated during the development stage	Total
	Shares	Amount	Shares	Amount				
Balance at December 31, 2010	1,685,341	\$ 169	10	\$ -	\$ 3,727,181	\$ -	\$ (806,334)	\$ 2,921,016
Common stock issued in 2011	3,396,009	339	-	-	34,749	-	-	35,088
Contributed capital	-	-	-	-	22,400	-	-	22,400
Share Exchange Agreement	38,250,000	3,825	382,500	38	(3,863)	-	-	-
Adjustment for disposition of intangible assets	-	-	-	-	(3,465,337)	-	-	(3,465,337)
Forgiveness of debt	-	-	-	-	877,365	-	-	877,365
Common stock issued for debt	75,000,000	7,500	-	-	67,500	-	-	75,000
Shares issued for intellectual property	600,000,000	60,000	3,500,000	350	139,650	-	-	200,000
Net loss for the year ended December 31, 2011	-	-	-	-	-	-	(69,769)	(69,769)
Balance at December 31, 2011	718,331,350	71,833	3,882,510	388	1,399,645	-	(876,103)	595,763
Common stock issued for services	50,000	5	-	-	16,495	-	-	16,500
Common stock issued for cash	8,449,200	845	-	-	161,114	(2,500)	-	159,459
Net loss for the year ended December 31, 2012	-	-	-	-	-	-	(841,138)	(841,138)
Balance at December 31, 2012	726,830,550	72,683	3,882,510	\$ 388	\$ 1,577,254	\$ (2,500)	\$ (1,717,241)	\$ (69,416)
Common stock issued for services	130,000	13	-	-	7,387	-	-	7,400

Common stock issued for cash	3,244,200	324	-	-	114,676	2,500	-	117,500
Common stock issued for acquisition	21,500,000	2,150	-	-	6,232,850	-	-	6,235,000
Contributed capital	-	-	-	-	2,000	-	-	2,000
Common stock issued for lock up agreements	1,959,000	196	-	-	195,704	-	-	195,900
Net loss for the period ended September 30, 2013	-	-	-	-	-	-	(387,846)	(387,846)
Balance at September 30, 2013	<u>753,663,750</u>	<u>\$ 75,366</u>	<u>3,882,510</u>	<u>\$ 388</u>	<u>\$ 8,129,871</u>	<u>-</u>	<u>\$ (2,105,087)</u>	<u>\$ 6,100,538</u>

The accompanying notes are an integral part of these unaudited consolidated financial statements.

**Viratech Corp.**  
**Notes to Unaudited Consolidated Financial Statements**  
**September 30, 2013**

**NOTE 1 - ORGANIZATION AND DESCRIPTION OF BUSINESS**

Viratech Corp., formerly known as Imperia Entertainment, Soleil Film and Television, Inc. Ameridream Entertainment, Inc. and Mc Smoothie's, Inc. (the Company) was incorporated under the laws of the state of California as Acquisition Solutions on March 21, 2000. It has acquired an extensive library of intellectual property focused on cancer prevention, detection and treatment and runs a social networking website focused on cancer research.

**NOTE 2 – PREPARATION OF FINANCIAL STATEMENTS**

The Company's unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP"). The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. These financial statements should be read in conjunction with the unaudited financial statements and footnotes for the year ended December 31, 2012. The results of the nine months ended September 30, 2013 are not necessarily indicative of the results to be expected for the full year ending December 31, 2013.

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Management further acknowledges that it is solely responsible for adopting sound accounting practices, establishing and maintaining a system of internal accounting control and preventing and detecting fraud. The Company's system of accounting internal control is designed to assure, among other items, that 1) recorded transactions are valid; 2) valid transactions are recorded; and 3) transactions are recorded in the proper period in a timely manner to produce financial statements which present fairly the financial condition, results of operations and cash flows of the Company for the respective periods being presented.

The Company is in the development stage as defined under Statement on Financial Accounting Standards Accounting Standards Codification FASB ASC 915-205 "Development-Stage Entities."

**NOTE 3 - SIGNIFICANT ACCOUNTING POLICIES**

*A. Cash and Cash Equivalents*

The Company considers all cash on hand and in banks, including accounts in book overdraft positions, certificates of deposit and other highly- liquid investments with maturities of three months or less, when purchased, to be cash and cash equivalents.

*B. Concentration of Credit Risk*

Financial instruments, which potentially subject the Company to concentration of credit risk, consist of cash deposits. The Company maintains cash with various major financial institutions. The Company performs periodic evaluations of the relative credit standing of these institutions. To reduce risk, the Company performs credit evaluations of its customers and maintains reserves for potential credit losses.

### *C. Principles of Consolidation*

The consolidated financial statements include the accounts of Viratech Corp and its subsidiary Cancer.im. All intercompany transactions are eliminated in consolidation.

### *D. Goodwill and other indefinite-lived intangibles*

The Company records the excess of purchase price over the fair value of the identifiable net assets acquired as goodwill and other indefinite-lived intangibles. The FASB standard on goodwill and other intangible assets, prescribes a two-step process for impairment testing of goodwill and indefinite-lived intangibles, which is performed annually, as well as when an event triggering impairment may have occurred. The first step tests for impairment, while the second step, if necessary, measures the impairment.

### *E. Property and Equipment*

Property and equipment are recorded at cost. Expenditures that increase the useful lives or capacities of the property and equipment are capitalized. Expenditures for repairs and maintenance are charged to expense as incurred.

### *F. Stock Based Compensation*

We follow ASC 718-10, "Stock Compensation", which addresses the accounting for transactions in which an entity exchanges its equity instruments for goods or services, with a primary focus on transactions in which an entity obtains employee services in share-based payment transactions. ASC 718-10 requires measurement of the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award (with limited exceptions). Incremental compensation costs arising from subsequent modifications of awards after the grant date must be recognized. The Company has not adopted a stock option plan and has not granted any stock options. The Company granted stock awards, at market value, to its advisors for services rendered. Accordingly, stock-based compensation has been recorded to date.

### *G. Income Taxes*

Income taxes are provided in accordance with Codifications topic 740, "Income Taxes", which requires an asset and liability approach for the financial accounting and reporting of income taxes. Current income tax expense (benefit) is the amount of income taxes expected to be payable (receivable) for the current year. A deferred tax asset and/or liability is computed for both the expected future impact of differences between the financial statement and tax bases of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carry forwards. Deferred income tax expense is generally the net change during the year in the deferred income tax asset and liability. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be "more likely than not" realized in future tax returns. Tax rate changes and changes in tax law are reflected in income in the period such changes are enacted

### *H. Earnings (Loss) Per Share*

Per Accounting Standards Codification Topic 260 "Earnings Per Share" (ASC 260), basic earnings (loss) per share are computed by dividing the net income (loss) by the weighted-average number of shares of common stock and common stock equivalents (primarily outstanding options and warrants). Common stock equivalents represent the dilutive effect of the assumed exercise of the outstanding stock options and warrants, using the treasury stock method. The calculation of fully diluted earnings (loss) per share assumes the dilutive effect of the exercise of outstanding options and warrants at either the beginning of the respective period presented or the date of issuance, whichever is later. As of the balance sheet dates the Company had no outstanding warrants.

### *I. Use of Estimates*

The preparation of financial statements in conformity with accounting principles generally accepted in the United States ("GAAP") requires management to make estimates and assumptions that affect (i) the reported amounts of assets and liabilities, (ii) the disclosure of contingent assets and liabilities known to exist as of the date the financial statements are published, and (iii) the reported amount of net sales and expenses recognized during the periods presented. Adjustments made with respect to the use of estimates often relate to improved information not previously

available. Uncertainties with respect to such estimates and assumptions are inherent in the preparation of financial statements; accordingly, actual results could differ from these estimates.

These estimates and assumptions also affect the reported amounts of revenues, costs and expenses during the reporting period. Management evaluates these estimates and assumptions on a regular basis. Actual results could differ from those estimates.

*J. J. Recent Accounting Pronouncements*

*K.*

In October 2012, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2012-04, "Technical Corrections and Improvements" in Accounting Standards Update No. 2012-04. The amendments in this update cover a wide range of Topics in the Accounting Standards Codification. These amendments include technical corrections and improvements to the Accounting Standards Codification and conforming amendments related to fair value measurements. The amendments in this update will be effective for fiscal periods beginning after December 15, 2012. The adoption of ASU 2012-04 is not expected to have a material impact on our financial position or results of operations.

In August 2012, the FASB issued ASU 2012-03, "Technical Amendments and Corrections to SEC Sections: Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin (SAB) No. 114, Technical Amendments Pursuant to SEC Release No. 33-9250, and Corrections Related to FASB Accounting Standards Update 2010-22 (SEC Update)" in Accounting Standards Update No. 2012-03. This update amends various SEC paragraphs pursuant to the issuance of SAB No. 114. The adoption of ASU 2012-03 is not expected to have a material impact on our financial position or results of operations.

In July 2012, the FASB issued ASU 2012-02, "Intangibles -Goodwill and Other (Topic 350): Testing Indefinite-Lived Intangible Assets for Impairment" in Accounting Standards Update No. 2012-02. This update amends ASU 2011-08, Intangibles -Goodwill and Other (Topic 350): Testing Indefinite-Lived Intangible Assets for Impairment and permits an entity first to assess qualitative factors to determine whether it is more likely than not that an indefinite-lived intangible asset is impaired as a basis for determining whether it is necessary to perform the quantitative impairment test in accordance with Subtopic 350-30, Intangibles -Goodwill and Other -General Intangibles Other than Goodwill. The amendments are effective for annual and interim impairment tests performed for fiscal years beginning after September 15, 2012. Early adoption is permitted, including for annual and interim impairment tests performed as of a date before July 27, 2012, if a public entity's financial statements for the most recent annual or interim period have not yet been issued or, for nonpublic entities, have not yet been made available for issuance. The adoption of ASU 2012-02 is not expected to have a material impact on our financial position or results of operations.

The Company has implemented all new accounting pronouncements that are in effect. These pronouncements did not have any material impact on the financial statements unless otherwise disclosed, and the Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

#### **NOTE 4 – IMPAIRMENT OF INTANGIBLE ASSETS**

The Company's new management has performed a thorough investigation of the assets and liabilities of the Company. As a result of this investigation, they have been unable to determine the appraised, depreciated value of the Company's film library. In addition, the Company determined that the value of its intellectual property had declined. As a result of these findings the Company has recorded a total loss on impairment as of December 31, 2012 of \$723,932.

]

#### **NOTE 5 – COMMON STOCK TRANSACTIONS**

During the period ended September 30, 2013, the Company issued 1,959,000 shares of common stock for total cash proceeds of \$195,900.

During the period ended September 30, 2013, the Company issued 130,000 shares of common stock to its CFO for services. Shares were valued at \$0.10, the closing price on the date of grant, for total expense of \$7,400.

During the period ended September 30, 2013, the Company issued 1,959,000 shares of common stock to its shareholders per the terms of a lock up agreement in which the shareholders agreed not to transfer their ownership shares for a specified time period. All shares were valued at \$0.10, as determined by management.

During the period ended September 30, 2013, the Company issued 21,500,000 shares of common stock for its acquisition of Cancer.im. Shares were valued at \$0.29, the price on the day the merger was authorized.

During the year ended December 31, 2012, the Company issued 8,449,200 for total cash proceeds of \$161,959, \$2,500 of which was collected in January 2013.

#### **NOTE 6 – ACQUISITION AND GOODWILL**

On January 15, 2013, the Company finalized the acquisition merger of Cancer.im, Inc. in exchange for 21,500,000 shares of Viratech restricted common stock. Cancer.im, Inc. owns and operates <http://cancer.im>, the world's first experienced-based social network resource site for cancer patients, survivors, advocates, and volunteers. Because the Company has not yet obtained an independent third party fair valuation of the Cancer.im website, the sole asset acquired, the full value of the issued stock of \$6,235,000 has been recorded as goodwill.

#### **NOTE 7 - RELATED PARTY TRANSACTION**

During the period ended September 30, 2013, the Company issued 130,000 shares of common stock to its CFO for services. Shares were valued at, the closing price on the date of grant, for total expense of \$7,400.

On December 18, 2012, the Company issued 50,000 shares of common stock to its newly appointed VP of Business Development. The shares were valued at \$0.33, the closing market price of the stock on the day of grant, for a total expense of \$16,500.

#### **NOTE 8 - SUBSEQUENT EVENTS**

Subsequent to September 30, 2013, the Company issued 100,000 shares of common stock for cash proceeds of \$2,500.

In accordance with ASC 855-10, the Company has analyzed its operations subsequent to August 31, 2013 through the date these financial statements were issued and has determined that it does not have any material subsequent events to disclose in these financial statement other than the events described above.